Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

Fig. 2

PD-1 inhibition yields increased pancreatic TIL. a Expression of PD-1 on TIL in digested pancreatic tumor samples was measured by flow cytometry. Representative data shown in flow plots as well as summary data of mean ± SD (n = 4). b After expansion, TIL were surface stained for CD3, CD4, CD8, and PD-1 and analyzed for PD-1 expression on CD3+ CD4+ or CD3+ CD8+ lymphocytes. Data are reported as mean % ± SD (n = 16). Pancreatic TIL were then propagated from fragments of pancreatic adenocarcinoma specimens in 6000 IU/mL rhIL-2 in the presence of 10 μg/mL α-PD-1 or the isotype control (IgG) antibody. After 2 weeks, total TIL were counted (c), and assessed for viability (d). Fold change was normalized to the isotype control. Column graph displays mean values with positive SD shown. Percentages present the corresponding frequency in the PD-1 or control group (n = 3 patients). Statistical significance was determined by the Wilcoxon signed rank test

Back to article page